Next Breath, LLC Accredited by World Health Organization (WHO) as an Independent Testing Laboratory For Nasal Vaccines

Next Breath, LLC Accredited by World Health Organization (WHO) as an Independent Testing Laboratory For Nasal Vaccines

Baltimore, MD (PRWEB) March 21, 2012

WHO and Performance Quality System (PQS) have completed their evaluation of Next Breath as a testing facility for nasal spray vaccine administration. As a result, Next Breath will be listed as a WHO PQS accredited facility for testing nasal sprayed vaccines.

Next Breath has met the accreditation process and Quality Assurance requirement of the WHO PQS as a testing laboratory for nasal vaccines. By this accreditation, Next Breath demonstrated its competency by conforming to appropriate internationally and nationally accepted standards or codes of practice. In addition, the accreditation allows Next Breath to carry out analytical testing of PQS products. Next Breath's accreditation in the WHO PQS system can be viewed at:

"The nasal delivery of vaccines has emerged as an attractive alternative to injection. Nasal vaccination has the advantage that it elicits both local and systemic immune responses. This accreditation is good news for vaccine developing companies looking for a specialized CRO for support in the nasal drug delivery of vaccines," Julie D. Suman, Ph.D.

About Next Breath

Next Breath is a cGMP contract services organization for pharmaceutical, biotech and medical device companies that bring inhalation and nasal products to market. Next Breath provides comprehensive solutions to the development processes for oral, inhaled, and nasal drug products. Our in vitro services range from pre-clinical formulation development to analytical testing in support of submissions to regulatory agencies. Next Breath has led successful submissions for pulmonary and nasal drug products and devices in the US and international markets.

For more information please contact Badre Hammond, MBA at 352-642-2141 or visit

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.